Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice.
Dietary quercetin and resveratrol have been frequently used in treating various diseases, but the underlying mechanisms are not entirely clear. Here, we report combined transcriptomic and metabonomic profiling that showed that the combined supplementation with quercetin and resveratrol produced synergistic effects on a high-fat diet-induced metabolic phenotype in mice. Histological and phenotypic improvements in serum and hepatic total cholesterol, insulin, fasting blood glucose, and HbA1c were also observed in mice receiving combined quercetin and resveratrol supplementation. This combined quercetin and resveratrol supplementation resulted in significant restoration of gene sets in functional pathways of glucose/lipid metabolism, liver function, cardiovascular system, and inflammation/immunity, which were altered by high fat diet feeding. The integration of transcriptomic and metabonomic data indicated quercetin and resveratrol supplementation enhanced processes of glycolysis and fatty acid oxidation, as well as suppressed gluconeogenesis. These alterations discovered at both the transcriptional and metabolic levels highlight the significance of combined "omics" platforms for elucidating mechanistic pathways altered by dietary polyphenols, such as quercetin and resveratrol, in a synergistic manner.
Center for Chinese Medical Therapy and Systems Biology, E-Institute, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Mingmei
M
Zhou
Shidong
S
Wang
Aihua
A
Zhao
Ke
K
Wang
Ziquan
Z
Fan
Hongzhou
H
Yang
Wen
W
Liao
Si
S
Bao
Linjing
L
Zhao
Yinan
Y
Zhang
Yongqing
Y
Yang
Yunping
Y
Qiu
Guoxiang
G
Xie
Houkai
H
Li
Wei
W
Jia
D000818:Animals; D001786:Blood Glucose; D050260:Carbohydrate Metabolism / Q000187:drug effects; D016000:Cluster Analysis; D059305:Diet, High-Fat / Q000009:adverse effects*; D019587:Dietary Supplements; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005234:Fatty Liver / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000378:metabolism*; D020869:Gene Expression Profiling; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D055442:Metabolome; D055432:Metabolomics; D051379:Mice; D008810:Mice, Inbred C57BL; D058977:Molecular Sequence Annotation; D020411:Oligonucleotide Array Sequence Analysis; D011794:Quercetin / Q000494:pharmacology* / Q000627:therapeutic use; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D059467:Transcriptome / Q000187:drug effects*
D001786:Blood Glucose; D008055:Lipids; D013267:Stilbenes; D011794:Quercetin; D000077185:Resveratrol